Antares Pharma Inc (NASDAQ:ATRS) – Stock analysts at Jefferies Financial Group issued their Q1 2019 earnings per share (EPS) estimates for Antares Pharma in a research report issued on Tuesday, November 6th. Jefferies Financial Group analyst A. Petrone expects that the specialty pharmaceutical company will post earnings of ($0.01) per share for the quarter. Jefferies Financial Group currently has a “Buy” rating and a $8.00 target price on the stock. Jefferies Financial Group also issued estimates for Antares Pharma’s Q2 2019 earnings at $0.00 EPS, Q3 2019 earnings at $0.00 EPS, Q4 2019 earnings at $0.01 EPS and FY2020 earnings at $0.06 EPS.
Antares Pharma (NASDAQ:ATRS) last issued its quarterly earnings data on Tuesday, November 6th. The specialty pharmaceutical company reported ($0.01) earnings per share for the quarter, beating the consensus estimate of ($0.02) by $0.01. Antares Pharma had a negative return on equity of 59.08% and a negative net margin of 27.84%. The business had revenue of $17.87 million for the quarter, compared to analysts’ expectations of $15.13 million.
Shares of NASDAQ:ATRS opened at $3.64 on Thursday. The company has a current ratio of 2.29, a quick ratio of 1.89 and a debt-to-equity ratio of 1.03. Antares Pharma has a 1-year low of $1.68 and a 1-year high of $3.93. The firm has a market cap of $557.70 million, a price-to-earnings ratio of -33.09 and a beta of 0.55.
In other news, Director Jacques Gonella sold 400,000 shares of Antares Pharma stock in a transaction on Tuesday, October 2nd. The stock was sold at an average price of $3.79, for a total transaction of $1,516,000.00. Following the sale, the director now directly owns 9,585,848 shares in the company, valued at approximately $36,330,363.92. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Robert F. Apple sold 43,000 shares of Antares Pharma stock in a transaction on Tuesday, August 21st. The stock was sold at an average price of $3.75, for a total value of $161,250.00. Following the sale, the chief executive officer now owns 1,573,562 shares in the company, valued at $5,900,857.50. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 492,507 shares of company stock worth $1,830,227. Company insiders own 12.20% of the company’s stock.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. raised its stake in shares of Antares Pharma by 1.3% during the 3rd quarter. BlackRock Inc. now owns 9,929,257 shares of the specialty pharmaceutical company’s stock worth $33,362,000 after purchasing an additional 123,932 shares during the period. FMR LLC raised its stake in shares of Antares Pharma by 38.8% during the 2nd quarter. FMR LLC now owns 3,640,800 shares of the specialty pharmaceutical company’s stock worth $9,393,000 after purchasing an additional 1,018,300 shares during the period. Mycio Wealth Partners LLC bought a new stake in shares of Antares Pharma during the 2nd quarter worth $6,278,000. JW Asset Management LLC raised its stake in shares of Antares Pharma by 5.5% during the 3rd quarter. JW Asset Management LLC now owns 1,920,524 shares of the specialty pharmaceutical company’s stock worth $6,453,000 after purchasing an additional 100,000 shares during the period. Finally, Northern Trust Corp raised its stake in shares of Antares Pharma by 7.4% during the 2nd quarter. Northern Trust Corp now owns 1,718,251 shares of the specialty pharmaceutical company’s stock worth $4,433,000 after purchasing an additional 119,091 shares during the period. Institutional investors own 38.62% of the company’s stock.
Antares Pharma Company Profile
Antares Pharma, Inc, a specialty pharmaceutical company, focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; and Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults.
Featured Article: The benefits and drawbacks of dollar cost averaging
Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.